

Merchant & Gould

An Intellectual Property Law Firm

3200 IDS Center
80 South Eighth Street
Minneapolis, Minnesota
55402-2215 USA
TEL 612.332.5300
FAX 612.332.9081
www.merchant-
gould.com

A Professional Corporation

Fax Transmission | June 18, 2004

TO: Commissioner for Patents
Attn: Examiner P. Duffy
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Rebecca Bortolotti

OUR REF: 12546.4USC1
TELEPHONE: 612.766.6045

Total pages, including cover letter: 13

PTO FAX NUMBER 1-703-872-9306

If you do NOT receive all of the pages, please telephone us at 612.766.6045, or fax us at 612.332.9081.

Title of Document Transmitted:
Applicant: Mercken et al.
Serial No.: 09/734,281
Filed: December 11, 2000
Group Art Unit: 1645
Our Ref. No.: 12546.4USC1
Confirmation No. 3720

Supplemental Amendment and Response

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: Rebecca Bortolotti
Name: Rebecca A. Bortolotti
Reg. No.: 51,488

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Rebecca Ralls

Rebecca Ralls
Signature

6/18/04
Date

GEN033.DOT

S/N 09/734,281

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEPATENT
RECEIVED

Applicant: MERCKEN ET AL. Examiner: P. DUFFY
Serial No.: 09/734,281 Group Art Unit: 1645
Filed: DECEMBER 11, 2000 Docket No.: 12546.4USC1
Title: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE
MICROTUBULE- ASSOCIATED PROTEIN TAU

CERTIFICATE UNDER 37 CFR 1.6(d): I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on June 18, 2004.

By: Rebecca Ralls
Name: Rebecca Ralls

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT AND RESPONSE

Dear Sir:

In response to the Final Office Action mailed on January 8, 2004, as well as the Advisory Action mailed on May 3, 2004, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 7 of this paper.